1 minute read
Jan. 17, 2022

Ulotaront: a TAAR1 GPCR Agonist with 5-HT1A Receptor Activity for Schizophrenia

ulotaront

TAAR1 GPCR agonist phase III candidate for schizophrenia from in vivo phenotypic screening ACS Medicinal Chemistry Letters Sunovion Pharmaceuticals, Marlborough, MA

drughunter.com
Drug Hunter Team
Reviewer:  

Ulotaront (SEP-363856) is a Phase III candidate with FDA Breakthrough Therapy Designation for the treatment of schizophrenia with demonstrated efficacy based on a physician-rated scale (PANSS) in a 4-week placebo-controlled trial and continued improvement in an open-label extension study. Reviewer Jake Schwarz says, “ulotaront was developed [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in